Aptiom Approval History

  • FDA approved: Yes (First approved November 8th, 2013)
  • Brand name: Aptiom
  • Generic name: eslicarbazepine acetate
  • Previous name: Stedesa
  • Company: Sunovion Pharmaceuticals Inc.
  • Treatment for: Epilepsy, Seizures

Aptiom (eslicarbazepine acetate) is a voltage-gated sodium channel blocker for the treatment of partial-onset seizures in adults with epilepsy.

FDA Approval History for Aptiom

DateArticle
Nov  8, 2013Approval FDA Approves Aptiom to Treat Seizures in Adults
Mar  8, 2013Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for Stedesa (eslicarbazepine acetate) as a Once-Daily Adjunctive Therapy for Partial-onset Seizures in Adults with Epilepsy
May  4, 2010FDA Provides Complete Response to Sepracor's New Drug Application for Stedesa
Jan 29, 2010FDA Extends PDUFA Action Date for Stedesa New Drug Application
Jun  1, 2009Sepracor's Stedesa (eslicarbazepine acetate) New Drug Application Formally Accepted for Review by the FDA
Mar 31, 2009Sepracor Announces Submission of Stedesa New Drug Application to FDA for Adjunctive Treatment of Epilepsy

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web2)